Medical information
12 articles shown
When Gallbladder Cancer Blocks the Bile Duct: Understanding Obstructive Jaundice and Biliary Drainage
How a blocked bile duct in gallbladder cancer causes obstructive jaundice, how biliary drainage with stents or PTBD restores bile flow, why the duodenum may also need a stent, warning signs to watch with a drain, and how to prepare for a second opinion.
Going to a Local Clinic for a 'Kidney IV' During Chemo — What Actually Protects Your Kidneys?
When kidney values rise during chemo, people look for a 'kidney IV,' but the real protection is adequate hydration with saline. This piece explains the meaning and limits of acetylcysteine, riboflavin, and amino-acid drips, and why kidney decisions should be coordinated with your oncology and nephrology teams.
Few Side Effects After Six Cycles of Chemotherapy — Why It Doesn't Mean the Drug Isn't Working, and Understanding the Timeline of Side Effects
The intensity of chemotherapy side effects does not reflect how well the drug works. This piece explains the typical timeline of side effects, why having few of them is not a sign of poor efficacy, and the warning signs worth reporting promptly.
Who Counts Your 'Lines of Therapy,' and Why Reusing a Targeted Drug Can Move You to the Next Line
A 'line of therapy' is a treatment strategy, not a count of infusions. Reusing a targeted drug after recurrence can change how lines are counted, and each drug has a defined coverage range — outside it, even out-of-pocket use may be barred. Learn how to confirm your line count and explore alternatives, appeals, and trials with your care team.
When One of Four Cancer Drugs Is Stopped Midway: Understanding 'Maintenance Therapy' and Easing Off Cytotoxic Chemo in Metastatic Stomach Cancer
In metastatic or advanced stomach cancer, cytotoxic chemotherapy is often started alongside targeted and immune therapies, then the more burdensome cytotoxic drug may be eased off while the rest continue—an approach called maintenance therapy. This explains why that is not giving up and why monitoring continues even after a drug is stopped.
Offered a "4 vs 8 cycles" clinical trial after stage 3 stomach cancer surgery — understanding trials that test a shorter course of chemotherapy
A plain-language look at clinical trials that compare a shorter versus longer course of adjuvant chemotherapy (such as 4 vs 8 cycles) after stage 3 stomach cancer surgery — what randomization means, that participation is voluntary, and questions to ask before deciding.
When HIPEC Is Suggested for Cancer That Has Spread to the Peritoneum — Understanding Cytoreductive Surgery, Recovery, and Follow-Up
A plain-language explanation of cytoreductive surgery with heated intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis, what recovery may look like, and how to make sense of follow-up tests like CEA and imaging.
When Platelet Counts Keep Falling During Chemoradiation — Understanding Bone Marrow Suppression and the Wish for a 'Food That Fixes It'
Why platelets often fall during combined chemotherapy and radiation (bone marrow suppression), why no single food quickly fixes the count, warning signs of bleeding, and how treatment schedules are safely adjusted.
"It's Standard Treatment, So It's the Same Everywhere" — Where a Doctor's Skill Still Fits In
Explains what "chemotherapy is standard treatment, so it's the same everywhere" really means, showing that within the same standard there is still room for a clinician's skill in drug choice, dosing, and side-effect management, and offering ways to settle the mind when second-guessing a treatment decision.
Scans Look Clean — So Why Recommend Removing the Stomach? Understanding the Limits of Imaging and Biopsy in Advanced Gastric Cancer
Even when CT, endoscopy, and biopsy come back clean after chemotherapy, finely scattered cancer cells can escape detection. This piece explains the difference between a clinical and a complete response, why surgery is often advised in advanced gastric cancer, and what to ask your care team.
Same FOLFIRI, Different Targeted Partner: How RAS Status and Tumor Location Shape Colorectal Cancer Chemotherapy
With the same FOLFIRI backbone, the added targeted drug (anti-EGFR vs anti-angiogenic) depends on RAS/BRAF mutation status, tumor location, and trial participation. This explains why combinations differ between patients.
When Your Chemo Dose Is Cut Because of Your Kidneys — Cisplatin and the Common Myth About a Salt-Free Diet
Cisplatin can stress the kidneys, so doses are often adjusted based on blood tests. The key to protecting the kidneys is adequate hydration rather than a salt-free diet, and diet or supplement changes should be guided by the care team.